title: Corneal wound healing modulation using basic fibroblast growth factor after excimer laser photorefractive keratectomy.
abstract: Photorefractive keratectomy with the 193-nm excimer laser is one of the most promising innovations in refractive surgery. However, routine clinical application is hindered by two main obstacles, i.e., postoperative subepithelial opacity and possible regression of the refractive result. Because we have previously demonstrated beneficial effects of basic fibroblast growth factor (bFGF) on corneal epithelial healing in different in vivo models, we investigated the influence on both epithelial and stromal healing of topical bFGF after excimer laser keratomileusis in a rabbit model. After 7-mm circular deepithelialization, the eyes of 24 New Zealand White rabbits received identical deep stromal laser ablations (depth 50 microns, 6 D, diameter 5 mm) and were randomly assigned to one of four treatment groups [control (phosphate-buffered saline, PBS), bFGF 10 micrograms/application, dexamethasone 0.1%, bFGF + dexamethasone, n = 12 eyes/group]. All treatments were administered four times daily--bFGF until complete epithelial healing, dexamethasone and PBS until 3 months postsurgery. Wound surface regression on time was determined by means of computer-assisted image analysis of fluorescein-stained corneas. Corneal opacity was observed biomicroscopically and graded using a previously established scoring system. After bFGF application for 2-3 days only, a highly significant acceleration in epithelial wound healing speed was found compared with the rate of the other three treatment groups (p < 0.001). A combined therapy (bFGF + steroid) had no effect on the healing rate. Compared with control values, mean scores for subepithelial haze in the other groups were found to be nearly 50% lower during the first 2 postoperative months.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Ophthalmology, Hôtel-Dieu Hospital, Paris, France.
authors.forename: T
authors.initials: T
authors.lastname: David
authors.forename: P
authors.initials: P
authors.lastname: Rieck
authors.forename: G
authors.initials: G
authors.lastname: Renard
authors.forename: C
authors.initials: C
authors.lastname: Hartmann
authors.forename: Y
authors.initials: Y
authors.lastname: Courtois
authors.forename: Y
authors.initials: Y
authors.lastname: Pouliquen
mesh_terms: D000818:Animals; D003315:Cornea / Q000187:drug effects* / Q000502:physiology / Q000601:surgery*; D003318:Corneal Opacity / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D003319:Corneal Stroma / Q000187:drug effects / Q000502:physiology; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004848:Epithelium / Q000187:drug effects / Q000502:physiology / Q000601:surgery; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage*; D053685:Laser Therapy / Q000009:adverse effects; D008297:Male; D009883:Ophthalmic Solutions; D011817:Rabbits; D011897:Random Allocation; D011994:Recombinant Proteins / Q000008:administration & dosage; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D009883:Ophthalmic Solutions; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2; D003907:Dexamethasone